- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT07294313
Nutzung Künstlicher Intelligenz zur Diagnose von androgenetischer Alopezie: Eine Trainings- und Validierungsstudie.
Nutzung künstlicher Intelligenz zur Diagnose von androgenetischer Alopezie: Eine Trainings- und Validierungsstudie.
The aim of this study is to develop and validate deep learning models in diagnosis of male and female pattern hair loss, and assessment of its severity based on clinical and trichoscopic image by handheld dermoscopy and administrative data (age and sex).
Studienübersicht
Status
Bedingungen
Detaillierte Beschreibung
The investigators intend to develop and validate artificial intelligence (AI) and machine learning (ML) models in diagnosis of male and female pattern hair loss, and assessment of its severity based on clinical and trichoscopic image using widely available and accessible handheld dermoscopes.
Conventional androgenetic alopecia (AGA) diagnosis and severity assessment are tedious and time-consuming tasks that are prone to human errors. These challenges can be tackled using artificial intelligence (AI), namely leveraging applications of machine learning and artificial neural networks for enhancing the diagnostic accuracy of scalp disease classification systems via dermoscopic image analysis. Computer aided assessment of hair microphotographs was attempted for decades, yet it faced many technical hurdles before the onset of deep learning and neural networks; and currently available software generate inaccurate results compared with visual counting. More accurate methods of analysis are needed for trichoscopic imaging, utilising deep learning image recognition models trained with a large image dataset. A number of deep learning models have been developed in recent years using videodermoscopy that achieved reliable hair density, thickness and severity classification, yet remain limited by small non-inclusive training datasets, need for hair shaving and lack of detailed reporting. Moreover, to our knowledge all previous models depend on image acquisition from expensive standalone videodermoscopy devices that lack widespread availability, rather than handheld dermoscopes that are commonly available.
The study will enroll 400 participants (200 healthy controls and 200 AGA patients). Controls undergo history and trichoscopic exams to exclude hair disorders. Trichoscopic examination will be conducted using a handheld dermoscope (CuTechs DS175) with a specialized field spacer. Patients will be assessed for disease severity using gender-specific scales. Both groups will have standardized digital and trichoscopic images taken for analysis. Images will be used to manually count and classify hairs, assess follicle units, and identify dermoscopic signs. A structured database will store all data and link clinical and image data to support objective diagnosis. AI models, particularly CNNs using transfer learning, will be trained on preprocessed images for classification and severity scoring. Model performance will be evaluated using metrics like accuracy, precision, recall, F1-score, and AUC-ROC compared with metrics reported by expert trichologists to validate accuracy and reliability
Studientyp
Einschreibung (Geschätzt)
Kontakte und Standorte
Studienkontakt
- Name: Ahmed Mourad, MD
- Telefonnummer: 00201021534245
- E-Mail: ahmedmourad@kasralainy.edu.eg
Studieren Sie die Kontaktsicherung
- Name: Noura Nour, MSc, MBBCh
- Telefonnummer: 00201271451744
- E-Mail: nouraadel41929@postgrad.kasralainy.edu.eg
Studienorte
-
-
Cairo Governorate
-
Cairo, Cairo Governorate, Ägypten, 11553
- Rekrutierung
- Faculty of Medicine Cairo University
-
Kontakt:
- Noura Nour, MSc, MBBch
- Telefonnummer: 00201271451744
- E-Mail: nouraadel41929@postgrad.kasralainy.edu.eg
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Probenahmeverfahren
Studienpopulation
Patients diagnosed clinically and trichoscopically with androgenetic alopecia of both genders and apparently healthy controls.
Beschreibung
for the patient group:
Inclusion criteria:
- Patients with male or female pattern hair loss diagnosed clinically or suspected clinically and confirmed trichoscopically
- Age of disease onset 12-50 years old
- Both genders
- Any grade of androgenetic alopecia
- Any duration of androgenetic alopecia
- Any skin type
Exclusion criteria by clinical and trichoscopic examination:
- Patients with patchy hair loss or Telogen effluvium only.
- Patients with cicatricial alopecia or diffuse alopecia areata
- Patients with inflammatory scalp disorders (psoriasis, seborrheic dermatitis, lichen planopilaris and frontal fibrosing alopecia in a pattern distribution)
- Lack of patient cooperation.
for the control group: apparently healthy participants not suffering from the following: AGA, patchy hair loss, cicatricial alopecia, diffuse alopecia areata, inflammatory scalp disorders (psoriasis, seborrheic dermatitis, lichen planopilaris and frontal fibrosing alopecia in a pattern distribution).
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Beobachtungsmodelle: CASE_CONTROL
- Zeitperspektiven: PROSPECTIVE
Kohorten und Interventionen
Gruppe / Kohorte |
|---|
|
androgenetic alopecia
Patients diagnosed clinically and trichoscopically with androgenetic alopecia of both genders. The diagnosis of AGA requires fulfillment of the primary criterion, plus one or more of the secondary criteria, and absence of exclusion criteria:
|
|
normal controls
apparently normal participants not suffering from the following :
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
assessment of diagnostic capability of AI in AGA
Zeitfenster: 6 months
|
Assess accuracy, sensitivity, specificity and positive predictive value of the trained AI models in differentiating AGA affected from non-AGA affected subjects using their macroscopic and trichoscopic images. |
6 months
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
assessment of severity of androgenetic alopecia using AI
Zeitfenster: 6 months
|
Assess accuracy, sensitivity, specificity and positive predictive value of the trained AI models in assessment of severity of androgenetic alopecia as regards:
|
6 months
|
|
facilitation of AI assessment using macroscopic imagies
Zeitfenster: 6 months
|
To compare the model's diagnostic accuracy using the macroscopic versus trichoscopic images alone |
6 months
|
Mitarbeiter und Ermittler
Sponsor
Publikationen und hilfreiche Links
Allgemeine Veröffentlichungen
- Sacha JP, Caterino TL, Fisher BK, Carr GJ, Youngquist RS, D'Alessandro BM, Melione A, Canfield D, Bergfeld WF, Piliang MP, Kainkaryam R, Davis MG. Development and qualification of a machine learning algorithm for automated hair counting. Int J Cosmet Sci. 2021 Nov;43 Suppl 1:S34-S41. doi: 10.1111/ics.12735.
- Wang Y, Ding W, Yao M, Li Y, Wang M, Wang L, Li Z, Sun S, Yang M, Zhu Y, Zhou N. Diagnostic and grading criteria for androgenetic alopecia using dermoscopy. Skin Res Technol. 2024 Apr;30(4):e13649. doi: 10.1111/srt.13649.
- Kuczara A, Waskiel-Burnat A, Rakowska A, Olszewska M, Rudnicka L. Trichoscopy of Androgenetic Alopecia: A Systematic Review. J Clin Med. 2024 Mar 28;13(7):1962. doi: 10.3390/jcm13071962.
- Young AT, Xiong M, Pfau J, Keiser MJ, Wei ML. Artificial Intelligence in Dermatology: A Primer. J Invest Dermatol. 2020 Aug;140(8):1504-1512. doi: 10.1016/j.jid.2020.02.026. Epub 2020 Mar 27.
- Devjani S, Ezemma O, Kelley KJ, Stratton E, Senna M. Androgenetic Alopecia: Therapy Update. Drugs. 2023 Jun;83(8):701-715. doi: 10.1007/s40265-023-01880-x. Epub 2023 May 11.
- Bokhari L, Cottle P, Grimalt R, Kasprzak M, Sicinska J, Sinclair R, Tosti A. Efficiency of Hair Detection in Hair-to-Hair Matched Trichoscopy. Skin Appendage Disord. 2022 Sep;8(5):382-388. doi: 10.1159/000524345. Epub 2022 May 12.
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Geschätzt)
Primärer Abschluss (Geschätzt)
Studienabschluss (Geschätzt)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- MD-192-2025
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Beschreibung des IPD-Plans
relevant praticipant data shall be provided to researchers who request them on reasonable basis
IPD-Sharing-Zeitrahmen
from 2027 indefintely
IPD-Sharing-Zugriffskriterien
access will be provided to deidentified data including all study parameters
Art der unterstützenden IPD-Freigabeinformationen
- STUDIENPROTOKOLL
- SAFT
- ICF
- ANALYTIC_CODE
- CSR
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .